ライフサイエンスコーパス: obstructive

1 ar changes occur early in the development of obstructive airways disease.

2 association was observed between either the obstructive apnea-hypopnea index and any aggregation par

3 t polysomnography to determine SDB severity (obstructive apnea-hypopnea index).

4 o spermatogenic failure in patients with non-obstructive azoospermia (NOA) and severe oligospermia (S

5 The most severe form is non-obstructive azoospermia (NOA), which is, in part, caused

6 ression is repressed in hypertrophied BSM in obstructive bladder disease.

7 diminished BSM contractility associated with obstructive bladder disease.

8 g the clinically relevant treatment phase of obstructive bladder myopathy.

9 ool enabling estimation of the likelihood of obstructive CAD by combining a pre-test probability (PTP

10 d CACS-CL models predicted the prevalence of obstructive CAD more accurately in the validation cohort

11 he phenotypic profile that distinguishes non-obstructive CAD patients from no CAD patients is associa

12 hort with a goal to identify the role of non-obstructive CAD patients in CAD diagnostics.

13 The purpose of this study was to evaluate if obstructive CAD provides predictive value beyond its ass

14 , 400 to 1,000, and >1,000), the presence of obstructive CAD was not associated with higher risk than

15 dless of whether they have nonobstructive or obstructive CAD.

16 nd discrimination of patients with suspected obstructive CAD.

17 receiver-operating characteristic curves of obstructive CAD: for the PTP model, 72 (95% confidence i

18 with emergency resection (ER) for left-sided obstructive colon cancer (LSOCC) using propensity-score

19 Urological obstructive complications (UOC) affect up to 15% of kidn

20 gatston units; P<0.001), and the presence of obstructive coronary artery disease (54% versus 25%; P<0

21 Patients with obstructive coronary artery disease (CAD) are at high ri

22 The prevalence of obstructive coronary artery disease (CAD) in symptomatic

23 Selected patients with obstructive coronary artery disease benefit from revascu

24 Myocardial ischaemia resulting from obstructive coronary artery disease is a major cause of

25 ts with chronic kidney disease without overt obstructive coronary artery disease, but the mechanisms

26 In the absence of obstructive coronary artery disease, intravascular imagi

27 nd hemodynamic instability in the absence of obstructive coronary artery disease.

28 risk score, coronary artery calcium score or obstructive coronary artery stenoses.

29 prospectively recruited 90 patients with non-obstructive coronary atherosclerosis on baseline compute

30 A total of 86 patients with angina but no obstructive coronary disease underwent coronary pressure

31 Obstructive defect was uncommon (7%) and did not have an

32 higher CAC scores and number of vessels with obstructive disease (by CAC scores: 6.2 per 1,000 person

33 and diseases, including chronic respiratory obstructive disease (COPD), asthma, apnea, and others fo

34 We evaluated the prediction of obstructive disease from combined analysis of semiuprigh

35 ied by CAC burden and number of vessels with obstructive disease.

36 r dysfunction and symptoms in the absence of obstructive disease.

37 PY for CAC >1,000; by number of vessels with obstructive disease: 6.1 per 1,000 PY for no CAD to 34.7

38 -2014) included patients without evidence of obstructive epicardial coronary artery disease and healt

39 Nonculprit lesions were categorized as obstructive (>=70% stenosis by visual angiographic asses

40 sus 17+/-5 mm, P<0.001), while prevalence of obstructive HCM was greater in recent cohorts (peak grad

41 e of muscular mitral-aortic discontinuity in obstructive HCM.

42 ortic discontinuity in 5 young patients with obstructive HCM.

43 Obstructive hypertrophic cardiomyopathy (oHCM) is charac

44 of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy [MAVERICK-HCM];

45 M (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored the sa

46 al class, and health status in patients with obstructive hypertrophic cardiomyopathy.

47 ass cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy.

48 Obstructive jaundice is an uncommon presentation for pat

49 at when injected into newborn mice causes an obstructive jaundice phenotype with lower mortality rate

50 Obstructive lesions more commonly harbored vulnerable pl

51 sites, 2010-2018) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD), which involved 1272

52 LV(EV) between Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 and GOLD 4 COPD was re

53 rkers in 3,698 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-4 patients and 3,479 c

54 mined by using Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.

55 stratified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (GOLD 0, no COPD;

56 cording to the Global Initiative for Chronic Obstructive Lung Disease classification system (P = .001

57 with the 2017 Global Initiative for Chronic Obstructive Lung Disease criteria.

58 5% confidence interval, 3.39-12.2) for acute obstructive lung disease hospitalizations, 2.03 (1.43-2.

59 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease II-IV) who were carefully chara

60 in current and former Global Initiative for Obstructive Lung Disease stage 0 smokers predicted struc

61 a for COPD (defined as Global Initiative for Obstructive Lung Disease stage 0).

62 d according to Global Initiative for Chronic Obstructive Lung Disease stage higher than 1 (odds ratio

63 nfection in 17 Global Initiative for Chronic Obstructive Lung Disease stage II subjects with COPD and

64 patients with Global Initiative for Chronic Obstructive Lung Disease stage II-IV COPD and persistent

65 s performed on Global Initiative for Chronic Obstructive Lung Disease stage IV COPD lungs with TLOs.M

66 Emphysema and chronic obstructive lung disease were previously identified as m

67 The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2020 Report aims to provide a

68 we observed 117 acute hospitalizations with obstructive lung disease, 227 acute hospitalizations wit

69 ease, heart failure, stroke, asthma, chronic obstructive lung disease, and type 2 diabetes mellitus.

70 risk model's variables included sex, chronic obstructive lung disease, symptom duration, neutrophil c

71 tility of FVC/TLC in identifying features of obstructive lung disease.

72 such as hypertension, diabetes, and chronic obstructive lung disease.

73 ted therapeutic targets in the management of obstructive lung diseases.

74 in the development of therapeutics to treat obstructive lung diseases.

75 ps; hyposecretory (P = 0.006, P = 0.016) and obstructive MGD (P = 0.008, P = 0.006) relative to high-

76 with low meibum delivery (hyposecretory and obstructive MGD).

77 eyes had hyposecretory MGD; and 254 eyes had obstructive MGD.

78 ed in the kidney biopsies from patients with obstructive nephropathy (Ob).

79 Compared with obstructive non-TCFAs, obstructive TCFAs had similar les

80 COMPLETE trial, nearly 50% had at least one obstructive nonculprit lesion containing complex vulnera

81 lesion level, there were 58 TCFAs among 150 obstructive nonculprit lesions compared with 74 TCFAs am

82 outine percutaneous coronary intervention of obstructive nonculprit lesions in patients with ST-segme

83 unction and influencing both restrictive and obstructive patterns.

84 TD, suggesting that cessation attenuates the obstructive process.

85 .93) and children (1.39, 1.29-1.49), chronic obstructive pulmonary disease (1.70, 1.47-1.97), lung ca

86 ratio, 1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among tho

87 al fibrillation (6% versus 10%), and chronic obstructive pulmonary disease (4% versus 7%) in patients

88 onia (CAP) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) represent a major

89 thogenesis of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

90 46), were more likely to suffer from chronic obstructive pulmonary disease (COPD 30% vs 9.8%; p = 0.0

91 Chronic obstructive pulmonary disease (COPD) and asthma remain p

92 tion (NIV) is used for patients with chronic obstructive pulmonary disease (COPD) and chronic hyperca

93 y improves survival in patients with chronic obstructive pulmonary disease (COPD) and chronic severe

94 rom patients with smoking-associated chronic obstructive pulmonary disease (COPD) and from mice chron

95 ventilation (NIPPV) with outcomes in chronic obstructive pulmonary disease (COPD) and hypercapnia is

96 Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulm

97 therapy to appropriate patients with chronic obstructive pulmonary disease (COPD) and interstitial lu

98 at-risk groups such as patients with chronic obstructive pulmonary disease (COPD) are poorly understo

99 Patients with chronic obstructive pulmonary disease (COPD) are susceptible to

100 y, and changes in symptoms using the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test and

101 /VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) at risk of future e

102 ation is recommended for people with chronic obstructive pulmonary disease (COPD) by all major COPD c

103 uals without spirometric evidence of chronic obstructive pulmonary disease (COPD) by current diagnost

104 Rationale: Chronic obstructive pulmonary disease (COPD) can develop not onl

105 A relative drop in FEV(1) >=10% in chronic obstructive pulmonary disease (COPD) candidates was asso

106 er adults at high risk of developing chronic obstructive pulmonary disease (COPD) could lead to imple

107 United States receive a diagnosis of chronic obstructive pulmonary disease (COPD) each year, and it i

108 and former smokers with and without chronic obstructive pulmonary disease (COPD) enrolled in the pro

109 Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are p

110 Respiratory viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations.

111 Rationale: Chronic obstructive pulmonary disease (COPD) has been associated

112 Background Pulmonary imaging of chronic obstructive pulmonary disease (COPD) has focused on CT o

113 Background Smokers with chronic obstructive pulmonary disease (COPD) have smaller left v

114 ospitalizations for exacerbations of chronic obstructive pulmonary disease (COPD) improves exercise c

115 Comorbidities such as diabetes and chronic obstructive pulmonary disease (COPD) increase patients'

116 Chronic obstructive pulmonary disease (COPD) is a complex and he

117 Chronic obstructive pulmonary disease (COPD) is a debilitating l

118 Chronic obstructive pulmonary disease (COPD) is a lung disorder

119 Chronic obstructive pulmonary disease (COPD) is a progressive co

120 Chronic obstructive pulmonary disease (COPD) is characterized by

121 Chronic obstructive pulmonary disease (COPD) is characterized by

122 lerance to exercise in patients with chronic obstructive pulmonary disease (COPD) is not known.

123 Chronic obstructive pulmonary disease (COPD) is the most common

124 Chronic Obstructive Pulmonary Disease (COPD) is the third leadin

125 lung function assessment, asthma and chronic obstructive pulmonary disease (COPD) management, metabol

126 Chronic obstructive pulmonary disease (COPD) may originate in ea

127 s (0.8%; 0%-3.5%; n = 15), or stable chronic obstructive pulmonary disease (COPD) patients (1.2%; 0.3

128 Exercise intolerance is common in chronic obstructive pulmonary disease (COPD) patients.

129 r tertiary lymphoid organs (TLOs) in chronic obstructive pulmonary disease (COPD) progression.

130 ale: The decades-long progression of chronic obstructive pulmonary disease (COPD) renders identifying

131 Although chronic obstructive pulmonary disease (COPD) risk is strongly in

132 panic white smokers with and without chronic obstructive pulmonary disease (COPD) using blood samples

133 abilitation after an exacerbation of chronic obstructive pulmonary disease (COPD) was associated with

134 Rationale: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled cortic

135 ions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and asthma.

136 erous clinical conditions, including chronic obstructive pulmonary disease (COPD), and is associated

137 nditions (such as cancer, arthritis, chronic obstructive pulmonary disease (COPD), and others) are as

138 espiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary fibr

139 D), cerebrovascular accidents (CVA), chronic obstructive pulmonary disease (COPD), asthma, diabetes m

140 and may enable improved treatment of chronic obstructive pulmonary disease (COPD), asthma, or urinary

141 enotyping and risk stratification in chronic obstructive pulmonary disease (COPD), but few large long

142 nchyma of smokers that might overlap chronic obstructive pulmonary disease (COPD), but studies on the

143 Chronic obstructive pulmonary disease (COPD), diagnosed by reduc

144 deficiency (AATD) is associated with chronic obstructive pulmonary disease (COPD), even among never-s

145 Rationale: In patients with chronic obstructive pulmonary disease (COPD), increased activity

146 and lavage fluid of individuals with chronic obstructive pulmonary disease (COPD), when compared to h

147 An obesity paradox in chronic obstructive pulmonary disease (COPD), whereby overweight

148 life, is diminished in patients with chronic obstructive pulmonary disease (COPD), with mounting evid

149 Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD), yet much of COPD r

150 CF), non-CF bronchiectasis (BE), and chronic obstructive pulmonary disease (COPD).

151 have been associated with asthma and chronic obstructive pulmonary disease (COPD).

152 life, is diminished in patients with chronic obstructive pulmonary disease (COPD).

153 cytokine found to be associated with chronic obstructive pulmonary disease (COPD).

154 ia, and 1830 (1.1%) participants had chronic obstructive pulmonary disease (COPD).

155 s for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD).

156 s common in patients with asthma and chronic obstructive pulmonary disease (COPD).

157 way ecology is altered in asthma and chronic obstructive pulmonary disease (COPD).

158 l burden in patients with asthma and chronic obstructive pulmonary disease (COPD).

159 anism(s) of action of roflumilast in chronic obstructive pulmonary disease (COPD).

160 (RV shrinkage) are both described in chronic obstructive pulmonary disease (COPD).

161 AL fluid and plasma of subjects with chronic obstructive pulmonary disease (COPD).

162 such as silicosis, lung cancer, and chronic obstructive pulmonary disease (COPD).

163 such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).

164 g tissue and that from patients with chronic obstructive pulmonary disease (COPD).

165 ssues, including cystic fibrosis and chronic obstructive pulmonary disease (COPD).

166 (HTN), atrial fibrillation (AF), and chronic obstructive pulmonary disease (COPD).

167 Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD); however, more than

168 hic pulmonary fibrosis (n = 13), and chronic obstructive pulmonary disease (n = 15), were analyzed fo

169 , 4 of dementia (n = 1036), and 3 of chronic obstructive pulmonary disease (n = 441).

170 ), arterial hypertension (P = 0.45), chronic obstructive pulmonary disease (P = 0.73), chronic kidney

171 On multivariable analysis, chronic obstructive pulmonary disease (P=0.024), prior use of co

172 f presence of breathlessness, higher chronic obstructive pulmonary disease [COPD] prevalence, materna

173 UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbat

174 lopment of chronic diseases, such as chronic obstructive pulmonary disease and interstitial pulmonary

175 in the FSTL1 region corresponded to chronic obstructive pulmonary disease and lung function.Conclusi

176 ad to lifelong disabilities, such as chronic obstructive pulmonary disease and vision loss.

177 ng disease (ILD) is fast approaching chronic obstructive pulmonary disease as the number one indicati

178 il counts, and greater prevalence of chronic obstructive pulmonary disease at recruitment.

179 on and mortality among patients with chronic obstructive pulmonary disease but has not been well stud

180 concentrations in a heavy smoker and chronic obstructive pulmonary disease cohort, we confirmed the e

181 Increased risk of asthma and chronic obstructive pulmonary disease has been reported in peopl

182 eases, obesity, diabetes, asthma and chronic obstructive pulmonary disease have become major healthca

183 lt in ~300 000 premature deaths from chronic obstructive pulmonary disease in the two countries.

184 e, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable

185 ightly older and more likely to have chronic obstructive pulmonary disease or heart failure.

186 ectives: To determine whether PGD in chronic obstructive pulmonary disease or interstitial lung disea

187 Chronic obstructive pulmonary disease refers to a group of disea

188 , clade A, member 1), in determining chronic obstructive pulmonary disease risk and severity is contr

189 The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstra

190 the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticas

191 Coronary heart disease and asthma or chronic obstructive pulmonary disease were the most common comor

192 age III and IV, and 29 patients with chronic obstructive pulmonary disease were used as control subje

193 patients 65 years or younger without chronic obstructive pulmonary disease who were admitted to our h

194 he COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) cohort.Measurements and M

195 gnosis (interstitial lung disease or chronic obstructive pulmonary disease).

196 nclusion In women more than men with chronic obstructive pulmonary disease, a reduction in the estima

197 respiratory disease (severe asthma, chronic obstructive pulmonary disease, and bronchiectasis) were

198 ke, cancer, heart failure, dementia, chronic obstructive pulmonary disease, and cirrhosis were statis

199 ad to hypoxic spells such as asthma, chronic obstructive pulmonary disease, and obstructive sleep apn

200 or stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial d

201 mong patients suffering from cancer, chronic obstructive pulmonary disease, and several other chronic

202 icated conditions, including asthma, chronic obstructive pulmonary disease, and various autoimmune di

203 n-CAHs for pneumonia, heart failure, chronic obstructive pulmonary disease, arrhythmia, urinary tract

204 alysis-dependence, cancer diagnosis, chronic obstructive pulmonary disease, ascites, sepsis, smoking,

205 ol subjects, independent of smoking, chronic obstructive pulmonary disease, BMI, renin-angiotensin-al

206 C(2)HEST (coronary artery disease or chronic obstructive pulmonary disease, hypertension, elderly, sy

207 chest CT, such as for osteoporosis, chronic obstructive pulmonary disease, interstitial lung disease

208 ity, alcohol, sleep apnea, diabetes, chronic obstructive pulmonary disease, previous myocardial infar

209 In patients with asthma or chronic obstructive pulmonary disease, viral infections, includi

210 Smoking also causes chronic obstructive pulmonary disease, which is treated with bet

211 isease pathogenesis, for example, in chronic obstructive pulmonary disease, yet the mechanisms that r

212 of diabetes and recent evidence for chronic obstructive pulmonary disease-associated kidney injury.

213 In humans with chronic obstructive pulmonary disease-associated pulmonary hyper

214 d in the lungs of humans affected by chronic obstructive pulmonary disease-associated pulmonary hyper

215 risk factors except hypertension and chronic obstructive pulmonary disease.

216 00 cells/muL, smoking, drug use, and chronic obstructive pulmonary disease.

217 f airway diseases such as asthma and chronic obstructive pulmonary disease.

218 patocytes, causing liver disease and chronic obstructive pulmonary disease.

219 are widely used to treat asthma and chronic obstructive pulmonary disease.

220 outcomes of sepsis in patients with chronic obstructive pulmonary disease.

221 r cigarette smokers with and without chronic obstructive pulmonary disease.

222 respiratory diseases like asthma and chronic obstructive pulmonary disease.

223 yocardial infarction, and history of chronic obstructive pulmonary disease.

224 in such diseases as Alzheimer's and chronic obstructive pulmonary disease.

225 Pneumonia, acute chronic obstructive pulmonary disease/asthma exacerbation, septi

226 entilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and m

227 for patients suffering from asthma, chronic obstructive pulmonary disorder and stroke, and are promi

228 Lung function revealed a mixed obstructive-restrictive impairment with reduced FEV1 and

229 in septic shock, heart failure, hypovolemia, obstructive shock, and hemodilution and thus detected th

230 d Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apne

231 Obstructive sleep apnea (OSA) affects 17% of women and 3

232 Obstructive sleep apnea (OSA) and asthma are highly prev

233 f intermittent hypoxia (IH) in patients with obstructive sleep apnea (OSA) and cutaneous melanoma (CM

234 based on pharyngeal factors is important for obstructive sleep apnea (OSA) evaluation.

235 , chronic obstructive pulmonary disease, and obstructive sleep apnea (OSA) exhibit daily variance.

236 A high prevalence of obstructive sleep apnea (OSA) has been reported in Down

237 Traditionally, the presence and severity of obstructive sleep apnea (OSA) have been defined by the a

238 We determine whether obstructive sleep apnea (OSA) increases serum levels of

239 Obstructive sleep apnea (OSA) is a common disorder assoc

240 Obstructive sleep apnea (OSA) is a common sleep disorder

241 Obstructive sleep apnea (OSA) is a highly prevalent diso

242 Obstructive sleep apnea (OSA) is a very prevalent disord

243 Rationale: Obstructive sleep apnea (OSA) is associated with increas

244 mpact of intracranial hypertension (ICH) and obstructive sleep apnea (OSA) on optic nerve function in

245 ory event index (REI) in moderate and severe obstructive sleep apnea (OSA) patients requires elucidat

246 Many adults with obstructive sleep apnea (OSA) use device treatments inad

247 hypoxia (IH) is a hallmark manifestation of obstructive sleep apnea (OSA), a widespread disorder of

248 nale: Obesity is the primary risk factor for obstructive sleep apnea (OSA).

249 patients with chronic insomnia disorder and obstructive sleep apnea (OSA).

250 We found a link between obstructive sleep apnea and an elevated risk of stage 3

251 Given the high prevalence of obstructive sleep apnea and CKD among adults, further in

252 demographics and lifestyle behaviors, severe obstructive sleep apnea associated with increased risk o

253 table hypercapnic COPD undergo screening for obstructive sleep apnea before initiation of long-term N

254 Obstructive sleep apnea may be associated with developme

255 eepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive air

256 a-hypopnea index (events per hour) to define obstructive sleep apnea severity (normal, <5.0; mild, 5.

257 onal hazards regression was used to estimate obstructive sleep apnea severity with risk of incident C

258 Obstructive sleep apnea syndrome (OSAS) represents a sub

259 ), which includes primary snoring through to obstructive sleep apnea syndrome (OSAS), may cause compr

260 x, age, systemic hypertension, diabetes, and obstructive sleep apnea syndrome between September 2007

261 ry heart disease, migraine, hypotension, and obstructive sleep apnea syndrome.

262 sleepiness is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate

263 221 patients with OHS and coexistent severe obstructive sleep apnea), we compared the effectiveness

264 r control is critical to the pathogenesis of obstructive sleep apnea, a common and serious sleep-rela

265 tions including high altitude, lung disease, obstructive sleep apnea, and age-related CNS ischemia/hy

266 with other sleep disorders (e.g., insomnia, obstructive sleep apnea, and parasomnias).

267 During obstructive sleep apnea, elevation of CO(2) during apnea

268 We examined the association between obstructive sleep apnea, other sleep characteristics, an

269 addition, sleep disorders such as insomnia, obstructive sleep apnea, rapid eye movement sleep behavi

270 abetes mellitus, cardiovascular disease, and obstructive sleep apnea, resulting in significant health

271 research highlights the interactions between obstructive sleep apnea-hypopnea syndrome (OSAHS) and ca

272 the set of patient generated health data, an obstructive sleep apnea-hypopnea syndrome (OSAHS) monito

273 poxia (CIH) simulating a severe condition of obstructive sleep apnea.

274 Obstructive sleep apnoea (OSA) is characterised by inter

275 threshold is one of the main contributors to obstructive sleep apnoea (OSA) pathogenesis.

276 us responsiveness in people with and without obstructive sleep apnoea (OSA).

277 EEG) between patients with SS and those with obstructive sleep apnoea (OSA).

278 69 years (men and women) have mild to severe obstructive sleep apnoea and 425 million (399-450) adult

279 ibitors are currently in clinical trials for obstructive sleep apnoea and atrial fibrillation(16).

280 ittent hypercapnic hypoxia characteristic of obstructive sleep apnoea could promote hypertension by i

281 lts aged 30-69 years have moderate to severe obstructive sleep apnoea globally.

282 buting to increased risk for hypertension in obstructive sleep apnoea patients.

283 The increased awareness of obstructive sleep apnoea's (OSA) links to Alzheimer's di

284 f published data on the global prevalence of obstructive sleep apnoea, a disorder associated with maj

285 being hypertension, chronic kidney disease, obstructive sleep apnoea, and metabolic disease includin

286 g erectile dysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporosis and venous thromb

287 continuous positive airway pressure-treated obstructive sleep apnoea.

288 lar mechanism for elevated blood pressure in obstructive sleep apnoea.

289 Obstructive sleep-disordered breathing (SDB), which incl

290 Subjects with restrictive or obstructive spirometry pattern at baseline were excluded

291 everity grading, and treatment of sinusoidal obstructive syndrome among children, adolescents, and yo

292 tion and clinical presentation of sinusoidal obstructive syndrome between children and adults have re

293 used for the routine diagnosis of sinusoidal obstructive syndrome in children, adolescents, and young

294 Sinusoidal obstructive syndrome, also known as hepatic veno-occlusi

295 dolescents, and young adults with sinusoidal obstructive syndrome, and to facilitate international cl

296 d severity grading guidelines for sinusoidal obstructive syndrome, intended for implementation across

297 ions with extensive experience in sinusoidal obstructive syndrome.

298 On a patient level, at least one obstructive TCFA was observed in 44/93 (47%) of patients

299 Compared with obstructive non-TCFAs, obstructive TCFAs had similar lesion length (23.1 versus

300 LL group reported better continence and less obstructive urinary symptoms and improved quality of lif